Disease index

cancer breakthrough pain

Pain · 2007–2017

5decisions
2medicines
1carried consumer input
0individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
fentanyl citrate Initial treatment for dose titration of cancer patients with breakthrough pain (BTP) who are already receiving maintenance opioid therapy for chronic pain. Jul 2017 Recommended with restriction input received
fentanyl citrate Treatment of breakthrough cancer pain in patients receiving opioids for persistent pain who are unable to tolerate further escalation of short-acting opioids… Jul 2015 Recommended with restriction unclear
fentanyl Management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy and are unable to tolerate further escalation of… Mar 2014 Not recommended unclear
fentanyl Management of breakthrough pain in patients with cancer who are already receiving maintenance opioid therapy for chronic pain and are unable to tolerate… Mar 2014 Not recommended unclear
fentanyl citrate Treatment of breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent cancer pain and where further escalation… Nov 2007 Recommended with restriction no section in document

What the PBS pays

$15M in government benefit over 2024–25, across 322,106 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
fentanyl $7.7M
fentanyl citrate $7.7M

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.